Ex Parte Reexaminations Are Maintained by the PTO, Not the Petitioner
Contributed by Knobbe Martens. Originally published on Patexia; republished here as part of the LexDana archive.
Written by: Jacob R. Rosenbaum and Michael E. Salamy
IN RE: GESTURE TECHNOLOGY PARTNERS, LLC
Before Lourie, Bryson, and Chen. Appeal from the Patent Trial and Appeal Board.
Summary: The estoppel provision of 35 U.S.C. § 315(e)(1) does not apply to ongoing ex parte reexaminations because the petitioner does not “maintain” the proceeding, the Patent Office does.
Samsung Electronics (“Samsung”) requested ex parte reexamination of Gesture Technology Partners’ (“Gesture’s”) patent while two IPRs were also pending, one of which Samsung was a party to. The IPRs resulted in final written decisions invalidating all but two claims of Gesture’s patent. Gesture then petitioned to terminate the ex parte reexamination, arguing that Samsung, as a party to one of the IPRs, was estopped from maintaining the reexamination under the estoppel provision of 35 U.S.C. § 315(e)(1). The Patent Office denied the petition, concluding that the estoppel provision of § 315(e)(1) does not apply to ongoing ex parte reexaminations.
The Federal Circuit affirmed. The Federal Circuit explained that 35 U.S.C. § 315(e)(1) prohibits IPR petitioners from requesting or maintaining proceedings on any ground that the petitioner raised or reasonably could have raised during the IPR after the IPR decision issues. Because the Patent Office maintains the proceeding, and not the petitioner, the estoppel provision is inapplicable against the Patent Office for ongoing ex parte reexamination proceedings.
Editor: Sean Murray
More insights
Federal Circuit Affirms Invalidation of Patent for Lack of Enablement of Claims Directed to a Method of Treating a Patient with a Unit Dosage in Wyeth Llc v Astrazeneca Pharmaceuticals Lp
Written by : Eric Furman, Ph.D. and Ashley C. Morales Key Takeaway: Federal Circuit invalidates patent claims directed to a method for treating non-small cell lung cancer through administration of “a unit dosage” of an irreversible epidermal…
When About Becomes Indefinite Federal Circuit Provides Guidance for Life Science Patent Applications Regarding Limits of Approximation in Enviro Tech v Safe Foods
Written by : Jason J. Jardine and Kenneth O. Aruda, Ph.D. Key Takeaway: The term “about” remains useful in biotech and pharmaceutical claims, but only if the patent provides objective guidance about what the term means. Absent that guidance,…
When Any Patent Means No Patent Federal Circuit Reverses Non Specific Verdict
Written by : Brian C. Barnes and Sophia F. Zahn OLLNOVA TECHNOLOGIES LTD. v. ECOBEE TECHNOLOGIES ULC [OPINION] Before Chen , Cunningham, and Stark. Appeal from the United States District Court for the Eastern District of Texas. Summary : A verdict form…